Acta Neurologica Belgica

, Volume 113, Issue 1, pp 25–29 | Cite as

Use of Vitex agnus-castus in migrainous women with premenstrual syndrome: an open-label clinical observation

  • Anna AmbrosiniEmail author
  • Cherubino Di Lorenzo
  • Gianluca Coppola
  • Francesco Pierelli
Original Article


Premenstrual syndrome (PMS) affects most women during their reproductive life. Headache is regarded as a typical symptom of PMS and, close to menses, migrainous women could experience their worst migraine attacks. Vitex agnus-castus (VAC) is a phytopharmaceutical compound, considered worldwide to be a valid tool to treat PMS. Aim of this study is to explore if headache is ameliorate in migrainous women treated with VAC for PMS by an open-label clinical observation. Migrainous women with PMS were enrolled in the study and advised to assume a treatment with VAC (40 mg/day) for PMS for a 3-month period. Effects both on PMS and headache were assessed. Out of 107 women, 100 completed the 3-month treatment for PMS. Out of them, 66 women reported a dramatic reduction of PMS symptoms, 26 a mild reduction, and 8 no effect. Concerning migraine, 42 % of patients experienced a reduction higher than 50 % in frequency of monthly attacks, and 57 % of patients experienced a reduction higher than 50 % in monthly days with headache. No patients reported remarkable side effects. Pending a placebo-controlled trial to confirm our results, we observed that the use of VAC in migrainous women affected by PMS resulted to be safe and well tolerated, and may positively influence the frequency and duration of migraine attacks.


Vitex agnus-castus Premenstrual syndrome Migraine Chaste Tree Chasteberry 


Conflict of interest

The authors declare that they have no conflicts of interest.


  1. 1.
    Ginsburg KA, Dinsay R (2000) Premenstrual Syndrome. In: Ransom SB (ed) Practical strategies in obstetrics and gynecology. WB Saunders, Philadelphia, pp 684–694Google Scholar
  2. 2.
    American College of Obstetricians and Gynecologists (ACOG) (2000) Premenstrual syndrome. ACOG, Washington, DCGoogle Scholar
  3. 3.
    Dean BB, Borenstein JE, Knight K, Yonkers K (2006) Evaluating the criteria used for identification of PMS. J Womens Health 15:546–555CrossRefGoogle Scholar
  4. 4.
    American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders-IV, 4th edn. American Psychiatric Association, Washington, D.CGoogle Scholar
  5. 5.
    Halbreich U, Borenstein J, Pearlstein T, Kahn LS (2003) The prevalence, impairment, impact, and burden of premenstrual dysphoric disorder (PMS/PMDD). Psychoneuroendocrinology 28:S1–S23Google Scholar
  6. 6.
    Cupini LM, Matteis M, Troisi E et al (1995) Sex-hormone-related events in migrainous females. A clinical comparative study between migraine with aura and migraine without aura. Cephalalgia 15:140–144PubMedCrossRefGoogle Scholar
  7. 7.
    Headache Classification Subcommittee of the International Headache Society (2004) The International Classification of headache disorders, 2nd edn. Cephalalgia 24(Suppl. 1)Google Scholar
  8. 8.
    Johnson SR (2004) Premenstrual syndrome, premenstrual dysphoric disorder, and beyond: a clinical primer for practitioners. Obstet Gynecol 104:845–859PubMedCrossRefGoogle Scholar
  9. 9.
    Rapkin A (2003) A review of treatment of premenstrual syndrome and premenstrual dysphoric disorder. Psychoneuroendocrinology 28:39–53PubMedCrossRefGoogle Scholar
  10. 10.
    No authors listed (2001) Herbal treatment for PMS? Harv Womens Health Watch 8:7Google Scholar
  11. 11.
    Girman A, Lee R, Kligler B (2003) An integrative medicine approach to premenstrual syndrome. Am J Obstet Gynecol 188:S56–S65PubMedCrossRefGoogle Scholar
  12. 12.
    Loch EG, Selle H, Boblitz N (2000) Treatment of premenstrual syndrome with a phytopharmaceutical formulation containing Vitex agnus castus. J Women Health Gend Based Med 9:315–320CrossRefGoogle Scholar
  13. 13.
    Berger D, Schaffner W, Schrader E et al (2000) Efficacy of Vitex agnus castus L. extract Ze 440 in patients with pre-menstrual syndrome (PMS). Arch Gynecol Obstet 264:150–153PubMedCrossRefGoogle Scholar
  14. 14.
    Huddleston M, Jackson EA (2001) Is an extract of the fruit of agnus castus (chaste tree or chasteberry) effective for prevention of symptoms of premenstrual syndrome (PMS)? J Fam Pract 50:298PubMedGoogle Scholar
  15. 15.
    Prilepskaya VN, Ledina AV, Tagiyeva AV, Revazova FS (2006) Vitex agnus castus: successful treatment of moderate to severe premenstrual syndrome. Maturitas 55:S55–S863CrossRefGoogle Scholar
  16. 16.
    Halaska M, Beles P, Gorkow C, Sieder C (1999) Treatment of cyclical mastalgia with a solution containing a Vitex agnus castus extract: results of a placebo-controlled double-blind study. Breast 8:175–181PubMedCrossRefGoogle Scholar
  17. 17.
    Kilicdag EB, Tarim E, Bagis T et al (2004) Fructus agni casti and bromocriptine for treatment of hyperprolactinemia and mastalgia. Int J Gynaecol Obstet 85:292–293PubMedCrossRefGoogle Scholar
  18. 18.
    Merz PG, Gorkow C, Schrodter A et al (1996) The effects of a special agnus castus extract (BP1095E1) on prolactin secretion in healthy male subjects. Exp Clin Endocrinol Diabetes 104:447–453PubMedCrossRefGoogle Scholar
  19. 19.
    Daniele C, Thompson Coon J, Pittler MH, Ernst E (2005) Vitex agnus castus: a systematic review of adverse events. Drug Saf 28:319–332PubMedCrossRefGoogle Scholar
  20. 20.
    Italian Ministry of Health (2007) Elenco degli integratori alimentari: Registro aggiornato per prodotto.
  21. 21.
    Schellenberg R (2001) Treatment for the premenstrual syndrome with agnus castus fruit extract: prospective, randomised, placebo controlled study. BMJ 322(7279):134–137PubMedCrossRefGoogle Scholar
  22. 22.
    Tfelt-Hansen P, Block G, Dahlof C et al (2000) Guidelines for controlled trials of drugs in migraine: second edition. Cephalalgia 20:765–786PubMedCrossRefGoogle Scholar
  23. 23.
    Hu Y, Hou TT, Zhang QY et al (2007) Evaluation of the estrogenic activity of the constituents in the fruits of Vitex rotundifolia L. for the potential treatment of premenstrual syndrome. J Pharm Pharmacol 59:1307–1312PubMedCrossRefGoogle Scholar
  24. 24.
    Meier B, Berger D, Hoberg E et al (2000) Pharmacological activities of Vitex agnus-castus extracts in vitro. Phytomedicine 7:373–381PubMedCrossRefGoogle Scholar
  25. 25.
    Webster DE, Lu J, Chen SN et al (2006) Activation of the mu-opiate receptor by Vitex agnus-castus methanol extracts: implication for its use in PMS. J Ethnopharmacol 106:216–221PubMedCrossRefGoogle Scholar
  26. 26.
    Wuttke W, Jarry H, Christoffel V et al (2003) Chaste tree (Vitex agnus-castus)—pharmacology and clinical indications. Phytomedicine 10:348–357PubMedCrossRefGoogle Scholar
  27. 27.
    Jarry H, Spengler B, Wuttke W, Christoffel V (2006) In vitro assays for bioactivity-guided isolation of endocrine active compounds in Vitex agnus-castus. Maturitas 55:S26–S36CrossRefGoogle Scholar
  28. 28.
    Marotta F, Mao GS, Liu T et al (2006) Anti-inflammatory and neuroprotective effect of a phytoestrogen compound on rat microglia. Ann NY Acad Sci 1089:276–281PubMedCrossRefGoogle Scholar
  29. 29.
    Herzog AG (2007) Neuroactive properties of reproductive steroids. Headache 47:S68–S78PubMedCrossRefGoogle Scholar

Copyright information

© Belgian Neurological Society 2012

Authors and Affiliations

  • Anna Ambrosini
    • 1
    Email author
  • Cherubino Di Lorenzo
    • 2
  • Gianluca Coppola
    • 3
  • Francesco Pierelli
    • 1
    • 4
  1. 1.INM Neuromed, IRCCS, Headache ClinicPozzilli (Isernia)Italy
  2. 2.Don Carlo Gnocchi Onlus FoundationRomeItaly
  3. 3.Department of Neurophysiology of Vision and NeurophthalmologyG.B. Bietti Eye Foundation-IRCCSRomeItaly
  4. 4.Department of Medical and Surgical Sciences and Biotechnologies and ICOT“Sapienza” University of RomeLatinaItaly

Personalised recommendations